L J Egan
Overview
Explore the profile of L J Egan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ryan A, Colleran A, OGorman A, OFlynn L, Pindjacova J, Lohan P, et al.
Oncogene
. 2014 Apr;
34(12):1563-74.
PMID: 24704833
In a model of peritoneal metastasis in immune-competent mice, we show that nuclear factor (NF)-κB inhibition in CT26 colon cancer cells prevents metastasis. NF-κB inhibition, by stable overexpression of IκB-α...
2.
Lai X, Egan L
Oncogenesis
. 2013 Aug;
2:e62.
PMID: 23939014
Intestinal microbes promote the injurious effects of radiation on those tissues. However, the molecular factors mediating this effect are largely unknown. In this work, we explored the effects of orally...
3.
Kerr D, Harhen B, Okine B, Egan L, Finn D, Roche M
Br J Pharmacol
. 2012 Oct;
169(4):808-19.
PMID: 23043675
Background And Purpose: JZL184 is a selective inhibitor of monoacylglycerol lipase (MAGL), the enzyme that preferentially catabolizes the endocannabinoid 2-arachidonoyl glycerol (2-AG). Here, we have studied the effects of JZL184...
4.
Kerr D, Burke N, Ford G, Connor T, Harhen B, Egan L, et al.
Neuroscience
. 2011 Sep;
204:53-63.
PMID: 21952131
The endocannabinoid system is an important regulator of the nervous, neuroendocrine, and immune systems, thus representing a novel therapeutic target for stress-related neuroinflammatory and psychiatric disorders. However, there is a...
5.
6.
Egan L, Sandborn W
Drugs Today (Barc)
. 2004 Mar;
34(5):431-46.
PMID: 15010706
The drugs that are effective in inflammatory bowel disease (IBD) act by inhibiting the chronic unregulated intestinal inflammation in these patients. The mainstays of the drug therapy of IBD are...
7.
Egan L, Myhre G, Mays D, Dierkhising R, Kammer P, Murray J
Aliment Pharmacol Ther
. 2003 Jun;
17(12):1521-8.
PMID: 12823155
Background: The rate of metabolic inactivation of proton-pump inhibitors is determined by polymorphisms of CYP2C19. It is not known if CYP2C19 variant alleles affect responses to proton-pump inhibitor therapy in...
8.
Egan L, Tremaine W, Mays D, Lipsky J, Sandborn W
Inflamm Bowel Dis
. 2001 Jan;
6(4):286-9.
PMID: 11149561
Introduction: This study reports the clinical outcome, toxicity, and methotrexate pharmacokinetics after the addition of low-dose cyclosporine to methotrexate in patients with ulcerative colitis or Crohn's disease. Methods: Three patients...
9.
Egan L, Murray J
Dig Dis
. 2000 Nov;
18(2):58-63.
PMID: 11060468
Proton pump inhibitors are highly effective in the management of acid-peptic diseases. These drugs potently inhibit acid secretion from gastric parietal cells by irreversibly inhibiting activity of the H(+), K(+)...
10.
Egan L, Baron T
Endoscopy
. 2000 Jun;
32(6):492-4.
PMID: 10863920
Expandable metal biliary stents are reserved for patients with unresectable malignant biliary obstruction. Occasionally, these stents may cause complications necessitating removal. We describe successful endoscopic removal of a biliary Wallstent...